Shares of Medline opened 20.7% above their offer price in their Nasdaq debut on Wednesday, giving the medical supply giant a valuation of $46.03 billion. ...

Core Insights - Medline is debuting on the Nasdaq after raising $6.26 billion in one of the largest IPOs in recent years, selling over 216 million shares at $29 each, at the higher end of its anticipated range [1][6] - The company plans to use the IPO proceeds to reduce its debt [1] Company Performance - Medline sells over 335,000 medical and surgical products and has reported consistent annual sales growth since its founding [2] - For the first nine months of the year ending in September, Medline reported a net income of $977 million on revenues of $20.65 billion, an increase from $911 million in net income on $18.72 billion in revenue during the same period the previous year [2] Market Context - Medline's IPO is part of a recovering IPO market, although overall activity remains below the record levels of 2021; the $6.26 billion raised is the largest since Rivian's IPO in 2021 [3] - CEO Jim Boyle stated that the IPO is expected to enhance Medline's brand, positioning the company as the "Costco of healthcare" for its customers [4]

Core Viewpoint - Medline, a U.S. medical supplies giant, is set to debut on the Nasdaq with the largest initial public offering (IPO) of the year, raising $6.26 billion at a share price of $29, which gives the company a market value of at least $37 billion [1][2]. Group 1: IPO Details - Medline's IPO is the largest U.S. listing since Rivian's $13.7 billion deal in November 2021, with over 200 IPOs priced this year despite market volatility [2]. - The company will trade under the symbol "MDLN" on the Nasdaq [1]. Group 2: Company Background - Medline is described as "the largest company you've never heard of," emphasizing its extensive presence in the market despite limited advertising and marketing efforts [2]. - The company was acquired by three private equity firms—Blackstone, Carlyle, and Hellman & Friedman—in 2021 for $34 billion, marking the largest leveraged buyout since the financial crisis [3].

Core Viewpoint - Medline's initial public offering (IPO) is set to be the largest of 2025, raising $6.26 billion and valuing the company at approximately $39 billion, despite a challenging economic environment for U.S. stock markets [12][13][14]. Company Overview - Medline is a medical supplies manufacturer based in Northfield, Illinois, founded in 1966 by brothers Jim and John Mills [2]. - The company produces around 335,000 different medical and surgical products, operating 33 global facilities and serving customers in over 100 countries [3]. Financial Performance - For the nine months ending September 27, Medline reported net sales of $20.6 billion and a net income of $977 million, compared to $18.7 billion in net sales and $911 million in net income for the same period the previous year [4]. IPO Details - Medline's IPO shares were priced at $29 each, at the higher end of the expected range of $26 to $30 [10]. - A total of 216,034,482 shares of Class A common stock were made available in the IPO [11]. - The IPO is expected to list on the Nasdaq Global Select Market under the ticker "MDLN" [9]. Historical Context - Medline has a history of public offerings, having originally gone public in 1972 before being taken private in 1977 [5]. - In 2021, a group of private equity investors acquired a majority stake in Medline for $34 billion, marking the largest leveraged buyout since the 2008 financial crisis [6]. Market Impact - Medline's IPO surpasses other significant IPOs in 2025, including the $5.3 billion raised by Contemporary Amperex Technology and the $1.75 billion raised by Venture Global [14].

Core Insights - Medline's shares surged 41% in their trading debut, closing at $41 after raising $6.26 billion in its IPO, marking one of the largest IPOs in recent years [1][4][7] Group 1: IPO Details - Medline sold over 216 million shares at $29 each, at the higher end of its anticipated range of $26 to $30 [2] - The proceeds from the IPO will be used to pay down some of the company's debts [2] Group 2: Financial Performance - For the first nine months of the year ending in September, Medline reported a net income of $977 million on revenue of $20.65 billion, an increase from $911 million on $18.72 billion in the same period the previous year [3] Group 3: Market Context - The IPO marks a recovery in the IPO market, although activity remains below the record levels seen in 2021 [4] - The $6.26 billion raised makes it the largest IPO since Rivian's $11.93 billion in 2021 [4] Group 4: Company Vision - CEO Jim Boyle stated that the IPO is expected to enhance Medline's brand, aiming to position the company as the "Costco of healthcare" for medical equipment buyers [5]

Core Insights - Medline's IPO debuted at $29 per share, raising approximately $6.26 billion with an implied valuation near $50 billion, marking it as the largest listing of the year [1] - The company is backed by major investment firms including Blackstone, Carlyle, and Hellman & Friedman, and increased its offering to meet strong institutional demand [1] Financial Performance - Medline carries about $17 billion in debt from a 2021 leveraged buyout and plans to use IPO proceeds to repay senior secured term loans, which is viewed positively by credit rating agencies [3] - For the nine months ending September 2025, Medline reported approximately $1 billion in net income on $20.6 billion in revenue, with adjusted EBITDA of $2.7 billion and a margin of 13.3% [4] - Analysts suggest that if Medline allocates $3–$4 billion for debt repayment, it could reduce leverage ratios by 0.5–1.0x, which is significant but not transformative [4] Customer Relationships and Market Position - The company boasts a 98% Prime Vendor retention rate, indicating strong customer relationships that support consistent cash generation [5] - Medline sources one-third of its products in-house from 33 manufacturing facilities, while the remainder comes from over 500 suppliers across 40 countries [7] Tariff Challenges and Competitive Landscape - Medline faces tariff headwinds that could impact earnings before taxes by $325–$375 million in 2025 and an additional $150–$200 million in 2026, which may offset organic growth [6] - The company must decide whether to absorb tariff costs or pass them on to hospitals, with most healthcare distributors only able to pass through 40–50% of these costs [8] - The competitive landscape includes major players like Cardinal Health, McKesson, and Owens & Minor, which intensifies pricing pressures due to private-label penetration and customer consolidation [8] Future Outlook - Investors are advised to monitor the company's ability to achieve a net leverage target of 2.5–3.0x within 18–24 months, as interest coverage and debt levels will be closely scrutinized [5] - The success of the IPO will depend on effective execution in deleveraging, managing tariff impacts, and maintaining margin discipline [9]

Core Insights - Medline (MDLN) raised approximately $6.26 billion, making it the largest initial public offering (IPO) in the United States this year, indicating a renewed interest from investors in large healthcare companies [1][1]. Company Summary - Medline is a medical supplies provider that has successfully completed a significant fundraising round through its IPO [1]. - The successful IPO reflects a broader trend of investor confidence in the healthcare sector, particularly in large enterprises [1].

Company Overview - Medline has been a private company for 58 years with consecutive growth and is now seeking to go public to expand its voice and market presence [1][2] - The company aims to be the "Costco of healthcare," utilizing a membership model that provides value and savings to its customers [5] Financial Performance - Medline has a 99% customer retention rate and offers over 335,000 products from 29 million square feet of warehouse space in the US [6] - The company's margins are designed to support ongoing investments in the business, with a current margin of approximately 13% [7][8] - As of September, Medline reported a net debt of about $15 billion and a net debt to EBITDA ratio of 4.8%, with plans to reduce this to 3.25 through a $5 billion IPO, allocating $4 billion for debt reduction [10] Market Position and Strategy - Medline positions itself as a value player in the healthcare market, focusing on cost and price competitiveness [8] - The healthcare industry is facing challenges such as reimbursement cuts and shifts in care delivery, which Medline aims to navigate by providing timely and valuable solutions to its customers [12][13]

Core Viewpoint - Medline is set to launch the largest IPO in the U.S. stock market this year, aiming to raise approximately $6.26 billion, positioning itself as one of the highest-valued companies in the medical device sector following major players like Johnson & Johnson and Abbott [1][3]. Company Overview - Founded in 1966 by Jon and Jim Mills, Medline is a leading manufacturer and distributor of medical supplies, including gloves, surgical gowns, and examination tables [4]. - The company operates in North America alongside Cardinal Health and Owens & Minor, forming a major supply system for hospital supplies [4]. - Medline has transformed from a traditional manufacturer to a global leader in the medical supply chain over the past 40 years [4]. Financial Performance - For the nine months ending September 27, the company reported revenues of $20.6 billion and a net profit of $977 million, compared to $18.7 billion in revenue and $911 million in net profit in the same period last year [5]. - Fitch Ratings upgraded Medline's credit rating from BB+ to BBB-, facilitating the IPO process [5]. Market Context - The IPO occurs amid a cautious investment climate, with Medline's growth data highlighting its stable cash flow and capacity for expansion despite challenges in the global medical manufacturing industry [6]. - Medline's IPO is significant as it marks a major exit for private equity, with Blackstone, Carlyle Group, and Hellman & Friedman having acquired the company for $34 billion in 2021 [7]. Investor Interest - Medline has secured cornerstone investor commitments totaling up to $2.35 billion, with participation from notable investment firms such as Viking Global Investors and Morgan Stanley [8]. - The company's business model combines manufacturing scale with high turnover rates, boasting a projected gross margin of 32% for 2024, significantly above the industry average [8]. Future Outlook - Analysts view Medline's IPO as a key indicator of investor confidence in the healthcare sector and the broader capital market, especially given the company's resilience in a challenging economic environment [10]. - The success of this IPO may influence the pricing and types of future IPOs in 2026, with expectations for other large tech companies to enter the market [10].

④ 【华纳据称本周将拒绝派拉蒙收购要约】12月16日，据媒体援引知情人士透露，华纳兄弟探索（简称华纳）计划拒绝派拉蒙天舞上周提出的收购要 约，主要原因是对派拉蒙天舞的融资安排和其他交易条款存在担忧。华纳董事会经过审议后认为，公司与奈飞的现有协议在价值、确定性和条款方面都优 于派拉蒙天舞的提案。截至发稿，奈飞上涨1.83%。 每经记者｜岳楚鹏 每经编辑｜段炼 兰素英 ① 【三大期指齐涨】截至发稿，道指期货涨0.19%、标普500指数期货涨0.30%、纳指期货涨0.34%。 ② 【纳斯达克将迎来年内全球最大IPO】美东时间12月17日晚，纳斯达克交易所将迎来全球今年最大IPO Medline，股票代码"MDLN"。该IPO发行规模经 上调后，最终定价锁定在推介区间高位。具体来看，该公司将以每股29美元发行2.16亿股股票，拟融资约62.6亿美元，定价对应的公司估值约为390亿美 元。Medline现有股东涵盖黑石集团、凯雷集团及弗里德曼（Hellman & Friedman）三大私募巨头。早在2021年，这三家机构就以340亿美元联合收购 Medline多数股权，成为史上规模最大的杠杆收购之一。Medline由米 ...